Doctor Marzia Rigolli
Global Drug Development, San Diego (United States of America)
Membership:
ESC Professional Member
HFA Member
Biography
Dr. Rigolli is a Cardiologist and Physician-Scientist (MD, DPhil), currently serving as Executive Director, Cardio-Renal, in Clinical Development at Eli Lilly and Company. Her expertise spans cardiomyopathies, imaging, heart failure, and cardio-renal.
Trained at the University of Oxford, where she was awarded a DPhil, and at the University of Verona, Italy, her academic research examined imaging-based clinical outcomes and novel therapeutic targets in heart failure, aortic stenosis, and cardiomyopathies. At UC San Diego, she worked on rare cardiomyopathies and gene replacement therapy approaches.
In her biopharmaceutical career, she has led clinical trials across the cardiovascular portfolio, with focus on cardiac myosin inhibition in HFpEF and cardiomyopathies at MyoKardia and Bristol Myers Squibb. At Lilly, she advances innovative cardiovascular-renal therapies for patients with cardiometabolic disease.
Contributor content
Presentation
Presentation
Right ventricular dysfunction is associated with late mortality in severe aortic stenosis: results from a multi-centre outcome study in patients undergoing aortic valve replacement
Presentation
Right ventricular dysfunction detected by cardiovascular magnetic resonance is associated with late mortality in severe aortic stenosis
Presentation
COPD in symptomatic aortic stenosis: the importance of correct assessment for defining prognosis
Presentation
